These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 29896030)

  • 1. Pharmaceutical Approval Update.
    Choy M
    P T; 2018 Jun; 43(6):326-327. PubMed ID: 29896030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date.
    Beck KM; Sanchez IM; Yang EJ; Liao W
    Psoriasis (Auckl); 2018; 8():49-58. PubMed ID: 30214892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies to watch in 2019.
    Kaplon H; Reichert JM
    MAbs; 2019; 11(2):219-238. PubMed ID: 30516432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tildrakizumab: First Global Approval.
    Markham A
    Drugs; 2018 Jun; 78(8):845-849. PubMed ID: 29752706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis.
    Frampton JE
    Am J Clin Dermatol; 2019 Apr; 20(2):295-306. PubMed ID: 30924030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug Resistant HIV Drug Lauded, But Clinical Foundation Not Very Deep.
    Morrow T
    Manag Care; 2018 Jun; 27(6):31-33. PubMed ID: 29989910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Burosumab: First Global Approval.
    Lamb YN
    Drugs; 2018 Apr; 78(6):707-714. PubMed ID: 29679282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibalizumab-uiyk (Trogarzo) for multidrug-resistant HIV.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):68-69. PubMed ID: 29667947
    [No Abstract]   [Full Text] [Related]  

  • 9. Ilumya® (Tildrakizumab): A Newly Approved Interluekin-23 Antagonist for the Treatment of Plaque Psoriasis.
    Gupta AK; Versteeg SG; Abramovits W; Vincent KD
    Skinmed; 2018; 16(5):321-324. PubMed ID: 30413226
    [No Abstract]   [Full Text] [Related]  

  • 10. Burosumab in X-linked hypophosphatemia: a profile of its use in the USA.
    Lyseng-Williamson KA
    Drugs Ther Perspect; 2018; 34(11):497-506. PubMed ID: 30459508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
    Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibalizumab: First Global Approval.
    Markham A
    Drugs; 2018 May; 78(7):781-785. PubMed ID: 29675744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
    Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
    Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial.
    Whyte MP; Carpenter TO; Gottesman GS; Mao M; Skrinar A; San Martin J; Imel EA
    Lancet Diabetes Endocrinol; 2019 Mar; 7(3):189-199. PubMed ID: 30638856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.
    Papp KA; Reich K; Blauvelt A; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaci D; Li Q; Cichanowitz N; Green S; La Rosa C
    J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1098-1106. PubMed ID: 30838709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tildrakizumab (Ilumya) - another IL-23 antagonist for psoriasis.
    Med Lett Drugs Ther; 2019 Jan; 60(1563):4-6. PubMed ID: 30681661
    [No Abstract]   [Full Text] [Related]  

  • 17. Tildrakizumab in the treatment of psoriasis - literature review.
    Banaszczyk K
    Reumatologia; 2019; 57(4):234-238. PubMed ID: 31548750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.
    Blauvelt A; Reich K; Papp KA; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaçi D; Li Q; Cichanowitz N; Green S; La Rosa C
    Br J Dermatol; 2018 Sep; 179(3):615-622. PubMed ID: 29742274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tildrakizumab for the treatment of psoriasis.
    Bangert C; Kopp T
    Immunotherapy; 2018 Sep; 10(13):1105-1122. PubMed ID: 30081696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tildrakizumab: monoclonal antibody against IL-23p19 for moderate to severe psoriasis.
    Paton DM
    Drugs Today (Barc); 2018 Jul; 54(7):433-444. PubMed ID: 30090880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.